更新于：2024-06-29
Penicillin G Sodium
青霉素G钠
更新于：2024-06-29
概要
基本信息
原研机构 |
非在研机构- |
最高研发阶段批准上市 |
首次获批日期 (1942-01-01), |
最高研发阶段(中国)- |
特殊审评- |
登录后查看首次获批时间轴
结构
分子式C16H18N2NaO4S |
InChIKeyXFGIVHXZEANRAL-LQDWTQKMSA-N |
CAS号69-57-8 |
关联
20
项与 青霉素G钠 相关的临床试验Comparative Examination of the Postoperative Effects of Low-laser Treatment and Platelet-rich Fibrin Applications After Mandibular Impacted Wisdom Teeth Extraction
Staphylococcus Aureus Network Adaptive Platform Trial
Validate an Easy to Administer Algorithm to Define Penicillin (PCN-B-lactam) Allergy Status in Sexually Transmitted Disease (STD) Clinic Outpatients
100 项与 青霉素G钠 相关的临床结果
登录后查看更多信息
100 项与 青霉素G钠 相关的转化医学
登录后查看更多信息
100 项与 青霉素G钠 相关的专利（医药）
登录后查看更多信息
188
项与 青霉素G钠 相关的文献（医药）2023-01-01Frontiers in cellular and infection microbiology
Case Report: Detection of Treponema phagedenis in cerebrospinal fluid of a neurosyphilis patient by metagenomic next-generation sequencing.
作者: Zhao, Chenggui ; Wu, Guoqiu ; Gao, Wei ; Yuan, Chenyan ; Xu, Wei
Treponema phagedenis, a human commensal spirochete, has been reported world-wide as a key factor in the pathogenesis of bovine digital dermatitis. Here we report a case of T. phagedenis sequence detection in the cerebrospinal fluid (CSF) of a patient. The patient was diagnosed with neurosyphilis, and T. phagedenis was detected as the only microorganism in his CSF by metagenomic sequencing. The patient went through a round of penicillin therapy previously (2.4 million units of Benzathine Penicillin intramuscularly once a week for three weeks) that did not resolve the symptoms; after the diagnosis of neurosyphilis he was treated with Penicillin G Sodium 4.0 million units q4h intravenous for 14 days then his symptoms resolved. To the best of our knowledge, T. phagedenis has never been reported to be detected in a human's CSF before. This was also the first time it was detected by metagenomic next-generation sequencing. We propose that more etiological tests should be performed including culture and sequencing for more patients with syphilis, which will contribute to a deeper understanding of the pathogenicity of the spirochete.
2022-06-26World journal of clinical cases
Coinfection of Streptococcus suis and Nocardia asiatica in the human central nervous system: A case report
作者: Xue, Xin-Hong ; Chen, Ying-Ying
BACKGROUND:
Streptococcus suis (S. suis) is an anthropozoonotic pathogen that shows clinical manifestations of meningitis, septicemia, and arthritis in infected humans. Nocardia is another type of anthropozoonotic bacteria, with clinical manifestations of skin, lung, and brain abscesses in infected humans. Few intracranial infections caused by S. suis or Nocardia have been reported. To the best of our knowledge, no study has reported a patient with simultaneous intracranial infection by S. suis and Nocardia.
CASE SUMMARY:
A 66-year-old male presented at Liaocheng People's Hospital (Liaocheng, Shandong Province, China) reporting dizziness with nausea and vomiting. Metagenomic next-generation sequencing (mNGS) was performed on cerebrospinal fluid for examination, and the patient was diagnosed with suppurative meningitis caused by S. suis infection. He received anti-infection treatment with penicillin sodium and ceftriaxone. The patient's condition initially improved but then deteriorated. Further mNGS of cerebrospinal fluid revealed both S. suis and Nocardia. Imaging examination revealed a brain abscess. Furthermore, a mixed infection of S. suis and Nocardia was detected in the patient's central nervous system. The patient was treated with antibiotics and sulfamethoxazole. He was discharged after his condition improved.
CONCLUSION:
This case shows that the disease can be recurrent in patients with intracranial infection of a rare pathogen. The possibility of mixed infection should also be considered, especially in patients treated with immunosuppressive agents. mNGS of cerebrospinal fluid is a supplement to conventional microbial pathogen identification methods. Patients with unknown pathogen diagnosis, early extensive use of antibiotics and infection with rare pathogens can be diagnosed by the combination of conventional methods and mNGS of cerebrospinal fluid.
2022-05-01Journal of clinical pharmacy and therapeutics4区 · 医学
Evaluation of desensitization protocols to betalactam antibiotics
4区 · 医学
Article
作者: Gelis, Sonia ; Aranda, Laura ; López‐Cabezas, Carmen ; Bartra, Joan ; Soy Muner, Dolors ; Albanell‐Fernández, Marta ; González‐García, Rubén
WHAT IS KNOWN AND OBJECTIVE:
Betalactam antibiotics are the most frequent cause of hypersensitivity reactions. Rapid drug desensitization (RDD) is a technique that induces temporary tolerance to a drug allowing a patient to receive the optimal agent. The increased use of RDD and the lack of standardization among available protocols in terms of formulation, starting dose, number of steps and dosing frequency make it essential to determine the safety and appropriate management of these protocols, especially regarding reconstitution, diluents, stability and drug administration in order to guarantee reproducibility. We reviewed betalactam desensitization protocols in a tertiary hospital, in accordance with currently published practices and evaluated its use on patients over a period of three years.
METHODS:
(a) We performed a literature search in PubMed, MEDLINE and Google Scholar databases for case reports and/or systematic reviews describing desensitization protocols for betalactam antibiotics. Pharmacokinetic parameters and physicochemical stability were checked for each antibiotic. (b) We retrospectively reviewed inpatients undergoing our antibiotic desensitization protocols from February 2018 to January 2021. Data and outcomes of desensitization procedures were analysed.
RESULTS:
We developed nine RDD protocols: meropenem, ceftriaxone, ceftazidime, ampicillin, ceftolozane/tazobactam, cloxacillin, piperacillin/tazobactam, amoxicillin/clavulanate and penicillin G sodium. Five antibiotics have RDD protocols for two different doses, adjusted to patients with impaired renal function. Detailed data (diluent, total dose, volume, concentrations, duration and stability) of the protocol of each antibiotic used are provided. 28 desensitizations were performed in 17 patients, three of them with confirmed allergies by skin test. 26 out of 28 (92.9%) of them were successfully completed, including those three with positive skin results. The pathogens most frequently involved were E. faecalis and P. aeruginosa; both frequently associated with bacterial resistance. Meropenem, ceftriaxone and ceftazidime were the antibiotics most desensitized. 25 out of 26 (96.1%) procedures were successful in resolving the infection.
WHAT IS NEW AND CONCLUSIONS:
Detailed information about compounding, dilution and stability is crucial to ensure safe and successful desensitization processes, as well as good coordination between the Allergy and Pharmacy departments. The increase in bacterial resistance to many of the commercially available antibiotics limits the therapeutic options for treating multidrug-resistant infections; in those situations, antibiotic desensitization may be a key therapeutic option. Although there is a broad consensus in limiting the use of RDD to patients with confirmed allergy, in usual clinical practice its application in those strongly suspected of having type I hypersensitivity is still observed. Our betalactam desensitization protocols have shown themselves to be safe and effective, as evidenced by data from the 17 patients on whom they have been tested.
100 项与 青霉素G钠 相关的药物交易
登录后查看更多信息
研发状态
10 条最早获批的记录, 后查看更多信息
登录
| 适应症 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|
| 细菌性心内膜炎 | 澳大利亚 | 1991-11-04 | |
| 脓毒症 | 澳大利亚 | 1991-11-04 | |
| 链球菌感染 | 澳大利亚 | 1991-11-04 | |
| 手术伤口感染 | 澳大利亚 | 1991-11-04 | |
| 梅毒 | 澳大利亚 | 1991-11-04 | |
| 细菌感染 | - | 1942-01-01 |
登录后查看更多信息
临床结果
临床结果
适应症
分期
评价
查看全部结果
N/A | 200 | (Penicillin and Metronidazole) | 鹹憲壓淵夢夢製窪廠顧(廠淵鏇觸鹹餘淵繭獵衊) = 廠憲襯醖繭淵製網簾鏇 淵鏇簾餘願艱獵願夢繭 (廠製繭夢觸壓製範窪鑰, 壓夢顧膚糧遞衊鑰壓範 ~ 範艱憲淵觸觸鏇衊築齋) 更多 | - | 2021-05-11 | ||
(Penicillin and Placebo) | 鹹憲壓淵夢夢製窪廠顧(廠淵鏇觸鹹餘淵繭獵衊) = 糧選觸蓋襯積鬱淵膚艱 淵鏇簾餘願艱獵願夢繭 (廠製繭夢觸壓製範窪鑰, 廠選膚願遞廠夢齋醖顧 ~ 獵製鑰艱製衊網蓋鏇餘) 更多 | ||||||
N/A | 133 | (Patients on antibiotic prophylaxis) | 鑰膚鑰夢壓醖鬱範壓網(鏇衊遞憲艱遞窪築齋顧) = 鹽觸願願鹹簾壓艱顧鏇 選膚壓製觸糧築糧積醖 (窪廠獵鹹淵廠顧淵簾選 ) | - | 2019-06-14 | ||
(Patients not on antibiotic prophylaxis) | 網鹹遞觸簾膚糧窪憲鹹(艱積齋選鹹鹽鏇觸鹽憲) = 簾構網顧構憲選壓鏇觸 鹹積壓鏇餘齋襯繭製獵 (膚衊願淵憲願壓糧獵繭 ) | ||||||
N/A | 31 | (HIV-positive patients with serological examined SI) | 構範壓蓋蓋顧鬱齋蓋觸(鑰製鏇鹽觸鹹製廠積願) = 襯艱製鏇憲範醖鬱觸製 窪築簾淵憲夢觸醖繭網 (構顧製鹽糧蓋膚範夢遞 ) 更多 | - | 2004-01-01 |
登录后查看更多信息
转化医学
使用我们的转化医学数据加速您的研究。
登录
或
药物交易
使用我们的药物交易数据加速您的研究。
登录
或
核心专利
使用我们的核心专利数据促进您的研究。
登录
或
临床分析
紧跟全球注册中心的最新临床试验。
登录
或
批准
利用最新的监管批准信息加速您的研究。
登录
或
特殊审评
只需点击几下即可了解关键药物信息。
登录
或
立即开始免费试用!
智慧芽新药情报库是智慧芽专为生命科学人士构建的基于AI的创新药情报平台，助您全方位提升您的研发与决策效率。
立即开始数据试用!
智慧芽新药库数据也通过智慧芽数据服务平台，以API或者数据包形式对外开放，助您更加充分利用智慧芽新药情报信息。
生物序列数据库
生物药研发创新
免费使用
化学结构数据库
小分子化药研发创新
免费使用